BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LXE408 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LXE408\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06632600-11263@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:LXE408: Phase 2 readout est. (NCT06632600)
DESCRIPTION:LXE408\, phase 2.\nStudy: A Study of Efficacy\, Safety\, Tolera
 bility of LXE408 in Participants With Chronic Chagas Disease.\nEstimated p
 rimary completion: 22 July 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/lxe408#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06632600
URL:https://assetmemo.bio/drug/lxe408#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06997159-11263@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280405
DTEND;VALUE=DATE:20280406
SUMMARY:LXE408: Phase 2 readout est. (NCT06997159)
DESCRIPTION:LXE408\, phase 2.\nStudy: A Clinical Trial to Investigate Effic
 acy\, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Ora
 l Miltefosine as Active Control in Participants Aged ≥ 18 Years Old With
  Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR).\nE
 stimated primary completion: 5 April 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/lxe408#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06997159
URL:https://assetmemo.bio/drug/lxe408#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
